Skip to main content
Premium Trial:

Request an Annual Quote

NIGMS to Support Systems Bio, Genetics Collaborations with $1.6M in ‘09

NEW YORK (GenomeWeb News) – The National Institute of General Medical Sciences plans to spend $1.6 million in the next fiscal year for programs that will support collaborations between geneticists and systems biologists to discover causes of complexity in human phenotypes, according to a recent request for applications from the National Institutes of Health.
The “Collaborative Studies on Systems Biology of Complex Phenotypes” grant program will fund three or four research programs for up to four years with up to $250,000.
The grant program requires collaboration between two independent investigators, one of whom must be a systems biologist and the other a geneticist.
The goal of the program is to study how complex human phenotypes are created from information encoded in DNA. Mendelian traits are not solely determined by the function of a single allele, NIH said, and a challenge in the foreseeable future will be to identify the collection of genes that can result in disease traits and how these genes and their products interact.
“The application of systems biology to genetics and genomics appears to be a promising approach to begin to understand the mechanisms underlying complex phenotypes,” NIH said in the RFA.
The long-term goal of the program is to understand the molecular mechanisms that underlie complex phenotypes so that they may be applied to improving health and diagnosing and treating disease.
Proposals should begin with observations of human conditions and then should formulate and test quantitative models that explain the underlying genetic mechanism.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more